Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1A1 | P14550 | 19/20 | 0.66 |
| ▸ | AKR1B1 | P15121 | 19/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5953411 | 0.88 | AKR1A1 (0.53) | AKR1A1AKR1B1 | |
| SCHEMBL9672199 | 0.83 | AKR1A1 (0.71) | AKR1A1AKR1B1 | |
| SCHEMBL9671730 | 0.83 | AKR1A1 (0.48) | AKR1A1AKR1B1 | |
| SCHEMBL20845825 | 0.82 | AKR1A1 (0.74) | AKR1A1AKR1B1 | |
| SCHEMBL25892758 | 0.81 | AKR1A1 (0.69) | AKR1A1AKR1B1 | |
| Imirestat SCHEMBL49034 | 0.81 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| Imirestat SCHEMBL30924520 | 0.81 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL9751281 | 0.80 | AKR1A1 (0.66) | AKR1A1AKR1B1 | |
| SCHEMBL21095644 | 0.78 | AKR1A1 (1.00) | AKR1A1AKR1B1 | |
| SCHEMBL20845814 | 0.77 | AKR1A1 (1.00) | AKR1A1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092566-A1 | Treatment of cancer with aldose reductase inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-21 | — | — | US | claimed |
| US-20100016404-A1 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE | 2010-01-21 | — | — | US | claimed |
| EP-2032145-A2 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | The Board of Regents of The University of Texas System (US) | 2009-03-11 | — | — | EP | claimed |
| WO-2008002678-A2 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-01-03 | — | — | WO | claimed |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2004-04-22 | — | — | US | claimed |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2003-04-03 | — | — | US | claimed |
| US-5521208-A | NONRACEMIC CHIRAL SPIROFLUORENEHYDANTOINS, ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1996-05-28 | — | — | US | claimed |
| WO-1995003800-A1 | NON-RACEMIC COMPOSITIONS OF SPIROFLUORENEHYDANTOINS | ALCON LABORATORIES, INC. (US) | 1995-02-09 | — | — | WO | claimed |
| US-12090142-B2 | Combination therapy for the treatment of cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-09-17 | — | — | US | disclosed |
| US-20210085650-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-03-25 | — | — | US | disclosed |
| WO-2019165195-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SRIVASTAVA SATISH (US) | 2019-08-29 | — | — | WO | disclosed |
| EP-3050593-B1 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | UNIV TEXAS (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-2654749-B1 | METHODS FOR TREATING COPD | UNIV TEXAS (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-3050593-A1 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | The Board of Regents of The University of Texas System (US) | 2016-08-03 | — | — | EP | disclosed |
| US-5521208-A | NONRACEMIC CHIRAL SPIROFLUORENEHYDANTOINS, ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1996-05-28 | — | — | US | disclosed |
| WO-1995003800-A1 | NON-RACEMIC COMPOSITIONS OF SPIROFLUORENEHYDANTOINS | ALCON LABORATORIES, INC. (US) | 1995-02-09 | — | — | WO | disclosed |
| US-5153211-A | Enzyme inhibitors | ALCON LABORATORIES, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5151544-A | Intermediates in the preparation of chiral spirofluorenehydantoins | ALCON LABORATORIES, INC. (US) | 1992-09-29 | — | — | US | disclosed |
| US-5070100-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1991-12-03 | — | — | US | disclosed |
| US-4864028-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1989-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | AKR1A1 11/4885AKR1B1 5/4885 |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | AKR1A1 11/4885AKR1B1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.